Search results for the GEO ID: GSE39339
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM966228
GPL570
Day 0, Patient 184 with good risk BCR-ABL patient with good risk before treatment (day 0) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: none time point: day 0 patient identifier: 184 GR_184_Day 0 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966229
GPL570
Day 0, Patient 193 with good risk BCR-ABL patient with good risk before treatment (day 0) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: none time point: day 0 patient identifier: 193 GR_193_Day 0 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966230
GPL570
Day 0, Patient 277 with good risk BCR-ABL patient with good risk before treatment (day 0) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: none time point: day 0 patient identifier: 277 GR_277_Day 0 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966231
GPL570
Day 0, Patient 341 with good risk BCR-ABL patient with good risk before treatment (day 0) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: none time point: day 0 patient identifier: 341 GR_341_Day 0 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966232
GPL570
Day 17, Patient 184 with good risk BCR-ABL patient with good risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 184 GR_184_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966233
GPL570
Day 17, Patient 256 with good risk BCR-ABL patient with good risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 256 GR_256_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966234
GPL570
Day 17, Patient 277 with good risk BCR-ABL patient with good risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 277 GR_277_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966235
GPL570
Day 17, Patient 319 with good risk BCR-ABL patient with good risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: good treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 319 GR_319_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966236
GPL570
Day 0, Patient 205 with poor risk BCR-ABL patient with poor risk before treatment (day 0) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: poor treatment: none time point: day 0 patient identifier: 205 PR_205_Day 0 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966237
GPL570
Day 0, Patient 241 with poor risk BCR-ABL patient with poor risk before treatment (day 0) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: poor treatment: none time point: day 0 patient identifier: 241 PR_241_Day 0 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966238
GPL570
Day 17, Patient 205 with poor risk BCR-ABL patient with poor risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: poor treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 205 PR_205_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966239
GPL570
Day 17, Patient 205 (replicate) with poor risk BCR-ABL patient with poor risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: poor treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 205 PR_205_rep_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966240
GPL570
Day 17, Patient 320 with poor risk BCR-ABL patient with poor risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: poor treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 320 PR_320_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966241
GPL570
Day 17, Patient 345with poor risk BCR-ABL patient with poor risk after treatment (day 17) tissue: bone marrow cells developmental stage: child disease state: Philadelphia positive acute lymphoblastic leukemia ((Ph+) ALL) risk: poor treatment: dexamethasone, anthracycline, vincristine, L-Asparaginase time point: day 17 patient identifier: 345 PR_345_Day 17 British Journal of Haematology 129 (6): 734-745, 2005 (PMID 15952999).
GSM966244
GPL570
0 h, CCRF-CEM-C7-14, biological rep1 CCRF-CEM-C7-14 before dexamethasone treatment (0 h) cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: none time point: 0 h T0-1 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966245
GPL570
0 h, CCRF-CEM-C7-14, biological rep2 CCRF-CEM-C7-14 before dexamethasone treatment (0 h) cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: none time point: 0 h T0-2 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966246
GPL570
0 h, CCRF-CEM-C7-14, biological rep3 CCRF-CEM-C7-14 before dexamethasone treatment (0 h) cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: none time point: 0 h T0-3 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966247
GPL570
2 h, CCRF-CEM-C7-14, biological rep1 CCRF-CEM-C7-14 with dexamethasone treatment for 2 h cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: dexamethasone time point: 2 h T2-1 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966248
GPL570
2 h, CCRF-CEM-C7-14, biological rep2 CCRF-CEM-C7-14 with dexamethasone treatment for 2 h cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: dexamethasone time point: 2 h T2-2 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966249
GPL570
2 h, CCRF-CEM-C7-14, biological rep3 CCRF-CEM-C7-14 with dexamethasone treatment for 2 h cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: dexamethasone time point: 2 h T2-3 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966250
GPL570
10 h, CCRF-CEM-C7-14, biological rep1 CCRF-CEM-C7-14 with dexamethasone treatment for 10 h cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: dexamethasone time point: 10 h T10-1 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
GSM966251
GPL570
10 h, CCRF-CEM-C7-14, biological rep2 CCRF-CEM-C7-14 with dexamethasone treatment for 10 h cell line: CCRF-CEM-C7-14 cell type: leukemia treatment: dexamethasone time point: 10 h T10-2 Cancer Research 58: 3684-3693, 1998 (PMID 9721879). ALL
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes